The over 30 antibiotic-resistant combinations ( xyz + PBT2) are valued at 1.3 M at the same time as "The Fund" invested 20M to a single company (Adaptive Phage) to get perhaps only 10% of the company.
This is my way of calculation. Everybody should do their own. Perhaps the fund has overestimated the value of Adaptive Phage.
Ann: Appendix 4C and Quarterly Cash Flow Report, page-10
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(11.1%) |
Mkt cap ! $26.60M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $1.288K | 257.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 97593686 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31319254 | 17 |
View Market Depth
| Last trade - 09.59am 26/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |